Answers are grounded in this paper and cite their sources.
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most common chronic liver disease worldwide, encompassing a spectrum from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, with the potential to progress to cirrhosis and hepatocellular carcinoma (HCC). While genetic factors influence disease risk, accumulating evidence highlights epigenetic regulation as a crucial factor connecting environmental and metabolic stressors to disease onset and progression. This narrative review adopts a stage-based approach, synthesizing current knowledge of epigenetic remodeling across the MASLD spectrum. We focus on three major epigenetic modulations, i.e. DNA methylation, histone modifications, and noncoding RNAs, and distinguish findings derived from human liver tissues, circulating biomarkers, and experimental models. This organization clarifies how epigenetic changes and shared regulatory pathways evolve throughout disease progression. Focusing on the Saudi Arabian context, we identify a substantial gap between the high regional burden of MASLD and the limited availability of liver-specific, longitudinal, and ancestry-aware epigenomic data. We propose research priorities and a framework to address these gaps, aiming to guide future studies in Saudi Arabia and the broader region toward clinically relevant biomarker discovery and precision hepatology.
No takes yet. Share an insight, caveat, or question.
Khalid et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: